abrdn Life Sciences Investors
HQL
67 hedge funds and large institutions have $94.2M invested in abrdn Life Sciences Investors in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
3% more funds holding
Funds holding: 65 → 67 (+2)
0% more capital invested
Capital invested by funds: $93.8M → $94.2M (+$462K)
2.11% less ownership
Funds ownership: 20.25% → 18.14% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$2.01M |
| 2 |
SFS
Shaker Financial Services
Arlington,
Virginia
|
+$816K |
| 3 |
Morgan Stanley
New York
|
+$560K |
| 4 |
AAM
Advisors Asset Management
Monument,
Colorado
|
+$359K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$4.22M |
| 2 |
MC
Matisse Capital
Portland,
Oregon
|
-$3.12M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.57M |
| 4 |
1CP
1607 Capital Partners
Richmond,
Virginia
|
-$986K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$811K |
HQL Hedge Fund Activity: Q2 2021 in Review
67 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2021, worth a combined $94.2M — up 0.49% from $93.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new HQL positions and 9 closed out — a net gain of 2 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was Stephens Inc, adding an estimated $2.01M. The largest seller was 1832 Asset Management, cutting an estimated $4.22M.
- 67 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2021, up from 65 in Q1 2021.
- Funds reported $94.2M of abrdn Life Sciences Investors stock for Q2 2021, up 0.49% quarter-over-quarter.
- 11 funds opened new abrdn Life Sciences Investors positions in Q2 2021 and 9 closed out, a net change of +2 holders.
- The largest abrdn Life Sciences Investors buyer in Q2 2021 was Stephens Inc, an estimated $2.01M added.
- The largest abrdn Life Sciences Investors seller in Q2 2021 was 1832 Asset Management, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2021.